The Technology and Life Sciences team advised Valo Health in the final closing of its Series B at $300 million, including a $110 million investment from Koch Disruptive Technologies. This brings the overall funding of Valo to over $450 million. With this investment, Valo will continue to scale its Opal Computational PlatformTM, the first-of-its-kind fully integrated end-to-end platform that combines machine learning-driven computational capabilities and patient data to develop first-in-class and best-in-class therapeutic programs across major disease areas.
Valo Health is a technology company that is using human-centric data and machine learning computation to transform the drug discovery and development process. As a digitally native company, Valo is the first to fully integrate human-centric data across the entire drug development lifecycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing the cost, time, and failure rate.
The Goodwin team was led by Stuart Cable and Joseph Theis and included Robert Dzialo.
For additional details on the funding round, please read the press release.